On Thursday, January 11, 2018, the Antimicrobial Drugs Advisory Committee (AMDAC) did not support, by a vote of 3-Yes to 12-No, with one abstention, the safety and efficacy of LinhaliqTM (ciprofloxacin dispersion for inhalation - Cipro DI), sponsored by Aradigm Corp. (Aradigm), for the proposed indication of treatment of non-cystic fibrosis bronchiectasis (NCFB or NCFBE) patients with chronic lung infections with Pseudomonas aeruginosa (P. aeruginosa).